This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ABT Stock Benefits From First Patient Procedures With TAVI System
by Zacks Equity Research
Abbott announces its investigational TAVI balloon-expandable system???s first patient procedures. This investigational TAVI system aims to offer best-in-class heart blood flow.
New Evidence on SAPIEN 3 Ultra RESILIA Valve Set to Boost EW Stock
by Zacks Equity Research
Edwards' SAPIEN 3 Ultra RESILIA Valve continues to deliver excellent outcomes for patients in real-world data.
International Expansion Supports BSX Stock Amid Macroeconomic Woes
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.
ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee
by Zacks Equity Research
Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval. The company plans a nationwide launch in the first quarter of 2025.
BSX Stock Set to Gain From Agreement to Acquire Intera Oncology
by Zacks Equity Research
Boston Scientific's new buyout is set to expand its interventional oncology offerings.
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
by Zacks Equity Research
The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions.
GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub
by Zacks Equity Research
Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation.
Reasons to Retain IART Stock in Your Portfolio for Now
by Zacks Equity Research
Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry.
Should You Hold IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Chemed Stock Hurt by Roto-Rooter Softness, Macro Issues Dent Growth
by Zacks Equity Research
The ongoing global economic conditions, such as general labor, supply chain and inflationary pressure, along with political and regulatory developments, are escalating expenses for CHE.
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns
by Zacks Equity Research
To support internal growth, QGEN heavily invests in R&D for the menu expansion of its key platforms.
MDT Stock Gains From FDA Approval for Its InPen App
by Zacks Equity Research
Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is concerning.
HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus
by Zacks Equity Research
Henry Schein inked a new agreement to acquire Acentus to enhance its ability to deliver CGM products directly to patients' homes.
ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander
by Zacks Equity Research
Align Technology achieves a CE mark for the Invisalign Palatal Expander System.
End Market Growth, New Acquisitions Drive Thermo Fisher's Shares
by Zacks Equity Research
A few of its recent strategic acquisitions that are likely to drive future growth for TMO include the $3.1-billion acquisition of Olink Holdings.
BellRing Brands Inc. (BRBR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
by Zacks Equity Research
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
by Zacks Equity Research
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Reasons to Retain BSX Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
by Zacks Equity Research
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
by Zacks Equity Research
BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
Here's Why You Should Add OMCL Stock to Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and long-term growth initiatives bode well for Omnicell.
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
by Zacks Equity Research
Exact Sciences presents new positive evidence backing the development of an MCED test.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?